European Expert Consortium to Develop a Novel Pandemic Flu Vaccine - - BioPharm International

ADVERTISEMENT

European Expert Consortium to Develop a Novel Pandemic Flu Vaccine

BioPharm Bulletin

Five European organizations, including three companies and two hospitals, have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination.

The four-year FluVac project, as it will be called, has been awarded a grant of €3.5 million from the European Union to help fund the research and the development of a new vaccine. Nobilon International BV will coordinate the project. The FluVac project consortium consists of Nobilon International BV (Boxmeer, the Netherlands), Protherics PLC (Cheshire, UK), Retroscreen Virology Ltd (London, UK), Erasmus Medical Centre (Rotterdam, the Netherlands), and Landspitali University Hospital (Reykjavik, Iceland).

Nobilon release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here